Anti-thrombotic Efficacies of Enoxaparin, Dalteparin, and Unfractionated Heparin in Venous Thrombo-embolism

By Morris T.A.   Marsh J.J.   Konopka R.   Pedersen C.A.   Chiles P.G.  

Thrombosis Research, Vol. 100, Iss. 3, 2000-11 ,pp. : 185-194

Elsevier

Access to resources Recommend Favorite

Anti-thrombotic activity of PDR, a newly synthesized l-Arg derivative, on three thrombosis models in rats

By Tang Z.   Wang Y.   Xiao Y.   Zhao M.   Peng S.  

Thrombosis Research, Vol. 110, Iss. 2, 2003-05 ,pp. : 127-133

Elsevier

Access to resources Recommend Favorite

Heparins with Reduced Anti-Coagulant Activity Reduce Myocardial Reperfusion Injury

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 6, Iss. 2, 2011-05 ,pp. : 148-157

Bentham Science Publishers

Access to resources Recommend Favorite

Comparing the Antithrombotic Efficacy of a Humanized Anti-factor IX(a) Monoclonal Antibody (SB 249417) to the Low Molecular Weight Heparin Enoxaparin In a Rat Model of Arterial Thrombosis

By Toomey J.R.   Blackburn M.N.   Storer B.L.   Valocik R.E.   Koster P.F.   Feuerstein G.Z.  

Thrombosis Research, Vol. 100, Iss. 1, 2000-10 ,pp. : 73-79

Elsevier

Access to resources Recommend Favorite

Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist

By Bostwick J.S.   Kasiewski C.J.   Chu V.   Klein S.I.   Sabatino R.D.   Perrone M.H.   Dunwiddie C.T.   Cook J.J.   Leadley R.J.  

Thrombosis Research, Vol. 82, Iss. 6, 1996-06 ,pp. : 495-507

Elsevier

Access to resources Recommend Favorite